Annotation Detail for ARHGEF10
Basic Information
Top
| Pathway ID | Pathway Name |
|---|
| 200050 | Regulation of RhoA activity |
| Desease Name |
|---|
| Slowed nerve conduction velocity, AD |
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| C023514 |
2,6-dinitrotoluene |
2,6-dinitrotoluene results in decreased expression of ARHGEF10 mRNA | decreases expression | 20406850
|
| D020122 |
tert-Butylhydroperoxide |
tert-Butylhydroperoxide results in decreased expression of ARHGEF10 mRNA | decreases expression | 15336504
|
| C014347 |
decitabine |
decitabine results in increased expression of ARHGEF10 mRNA | increases expression | 19194470
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D001943 |
Breast Neoplasms |
|
decitabine |
2.53 | 19208741 18320071 |
| MESH:D006528 |
Carcinoma, Hepatocellular |
|
2,6-dinitrotoluene |
1.79 | 16705839 |
| MESH:D002294 |
Carcinoma, Squamous Cell |
|
decitabine |
2.69 | 19215824 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
2,6-dinitrotoluene |
3.06 | 6135515 |
| MESH:D003110 |
Colonic Neoplasms |
|
decitabine |
2.39 | 17616700 |
| MESH:D015179 |
Colorectal Neoplasms |
|
decitabine |
2.11 | 18981723 |
| MESH:D003490 |
Cyanosis |
|
2,6-dinitrotoluene |
4.67 | 18551238 |
| MESH:D056486 |
Drug-Induced Liver Injury |
|
2,6-dinitrotoluene |
2.06 | 18551238 21346803 |
| MESH:D004701 |
Endocrine Gland Neoplasms |
|
decitabine |
5.98 | 19294695 |
| MESH:D006258 |
Head and Neck Neoplasms |
|
decitabine |
3.77 | 19215824 |
| MESH:D007248 |
Infertility, Male |
|
decitabine |
3.48 | 17581917 |
| MESH:D007680 |
Kidney Neoplasms |
|
2,6-dinitrotoluene |
3.36 | 16705839 |
| MESH:D007938 |
Leukemia |
|
decitabine |
3.25 | 18980019 19235587 |
| MESH:D007951 |
Leukemia, Myeloid |
|
decitabine |
4.49 | 17236224 19117987 18454857 |
| MESH:D015470 |
Leukemia, Myeloid, Acute |
|
decitabine |
2.43 | 17679729 19387464 18460780 18704418 19010910 18206229 |
| MESH:D015477 |
Leukemia, Myelomonocytic, Chronic |
|
decitabine |
6.33 | 18055864 |
| MESH:D008113 |
Liver Neoplasms |
|
2,6-dinitrotoluene |
2.28 | 7678174 |
| MESH:D008114 |
Liver Neoplasms, Experimental |
|
2,6-dinitrotoluene |
2.79 | 2876786 6135515 2876784 |
| MESH:D008223 |
Lymphoma |
|
decitabine |
3.73 | 19470736 |
| MESH:D008545 |
Melanoma |
|
decitabine |
2.29 | 16505122 17785578 |
| MESH:D009101 |
Multiple Myeloma |
|
decitabine |
3.65 | 18172295 |
| MESH:D009190 |
Myelodysplastic Syndromes |
|
decitabine |
3.60 | 18608210 19157545 19010910 16882708 |
| MESH:D009336 |
Necrosis |
|
2,6-dinitrotoluene |
4.60 | 7678174 18551238 |
| MESH:D009369 |
Neoplasms |
|
decitabine |
2.89 | 19116145 19470736 17925555 |
| MESH:D009784 |
Occupational Diseases |
|
2,6-dinitrotoluene |
3.88 | 16049721 |
| MESH:D010051 |
Ovarian Neoplasms |
|
decitabine |
2.75 | 19331143 19259094 |
| MESH:D010190 |
Pancreatic Neoplasms |
|
decitabine |
2.89 | 19294695 |
| MESH:D055728 |
Primary Myelofibrosis |
|
decitabine |
5.38 | 17616702 |
| MESH:D012208 |
Rhabdomyosarcoma |
|
decitabine |
4.93 | 19155313 |
| MESH:D012640 |
Seizures |
|
2,6-dinitrotoluene |
2.82 | 18551238 |
| MESH:D012878 |
Skin Neoplasms |
|
tert-Butylhydroperoxide |
2.86 | 8532709 |
| OMIM:608236 |
SLOWED NERVE CONDUCTION VELOCITY, AUTOSOMAL DOMINANT |
marker/mechanism |
|
| |
| MESH:D013274 |
Stomach Neoplasms |
|
decitabine |
2.10 | 19037991 |
| MESH:D013964 |
Thyroid Neoplasms |
|
decitabine |
3.67 | 17967635 |
| MESH:D001749 |
Urinary Bladder Neoplasms |
|
2,6-dinitrotoluene |
5.64 | 16049721 |
| MESH:D001749 |
Urinary Bladder Neoplasms |
|
decitabine |
5.64 | 17616700 19087683 |
| MESH:D014571 |
Urologic Neoplasms |
|
2,6-dinitrotoluene |
5.06 | 10091137 |
| MESH:D014604 |
Uveal Neoplasms |
|
decitabine |
5.78 | 17785578 |
Pharmacogenomics Knowledge Base